 |
 |
|
Cambridgeshire and Peterborough
Formulary |
| Formulary Chapter 4: Central nervous system - Full Section
|
| Useful Links |
 MHRA Drug Safety Update March 2020: Benzodiazepines and opioids - reminder of risk of potentially fatal respiratory depression |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
04.01 |
Hypnotics and anxiolytics
(0,1)
|
|
04.01.01 |
Hypnotics
(2,4)
|
|
|
Benzodiazepines
(2,2)
|
|
|
Zaleplon, Zolpidem and Zopiclone
(2,1)
|
|
|
Chloral and derivatives
(1,2)
|
|
|
Clomethiazole (Chlormethiazole)
(0,1)
|
|
|
Sodium oxybate
(1,0)
|
|
|
Pitolisant
(1,0)
|
|
04.01.02 |
Anxiolytics
(0,0)
|
|
|
Benzodiazepines
(5,1)
|
|
|
Buspirone
(1,0)
|
|
|
Meprobamate
(0,1)
|
|
04.01.03 |
Barbiturates
(0,2)
|
|
04.02 |
Drugs used in psychoses and related disorders
(0,1)
|
|
04.02.01 |
Antipsychotic Drugs
(8,6)
|
|
|
First-Generation Antipsychotic Drugs
(0,0)
|
|
|
Second-Generation Antipsychotic Drugs
(8,3)
|
|
04.02.02 |
Antipsychotic depot injections
(9,1)
|
|
04.02.03 |
Drugs used for mania and hypomania
(2,1)
|
|
|
Benzodiazepines
(0,0)
|
|
|
Carbamazepine
(1,0)
|
|
|
Valproic acid
(2,1)
|
|
|
Lithium
(4,2)
|
|
04.03 |
Antidepressant drugs
(0,0)
|
|
04.03.01 |
Tricyclic and related antidepressant drugs
(0,0)
|
|
|
Tricyclic antidepressants
(5,5)
|
|
|
Related antidepressants
(1,1)
|
|
04.03.02 |
Monoamine-oxidase inhibitors
(2,1)
|
|
|
Reverible MAOIs
(1,1)
|
|
04.03.03 |
Selective serotonin re-uptake inhibitors
(7,1)
|
|
04.03.04 |
Other antidepressant drugs
(3,4)
|
|
04.04 |
CNS stimulants and other drugs used for attention deficit hyperactivity disorder
(6,0)
|
|
04.05 |
Drugs used in the treatment of obesity
(0,0)
|
|
04.05.01 |
Anti-obesity drugs acting on the gastro-intestinal tract
(1,1)
|
|
04.05.02 |
Centrally acting appetite suppressants
(0,0)
|
|
04.06 |
Drugs used in nausea and vertigo
(0,0)
|
|
|
Antihistamines
(3,4)
|
|
|
Phenothiazines and related drugs
(5,2)
|
|
|
Domperidone and metoclopramide
(2,3)
|
|
|
5HT3 antagonists
(3,1)
|
|
|
Neurokinin receptor antagonist
(2,1)
|
|
|
Cannabinoid
(1,0)
|
|
|
Hyoscine
(1,0)
|
|
|
Other drugs for Ménière's disease
(1,0)
|
|
04.07 |
Analgesics
(0,0)
|
|
04.07.01 |
Non-opioid analgesics and compound analgesic preparations
(0,0)
|
|
|
Compound analgesic preparations
(2,6)
|
|
04.07.02 |
Opioid analgesics
(18,16)
|
|
04.07.03 |
Neuropathic pain
(6,0)
|
|
|
Trigeminal neuralgia
(2,0)
|
|
|
Postherpetic neuralgia
(1,0)
|
|
04.07.04 |
Antimigraine drugs
(0,0)
|
|
04.07.04.01 |
Treatment of the acute migraine attack
(0,0)
|
|
|
Analgesics
(0,4)
|
|
|
5HT1 agonists
(3,4)
|
|
|
Ergot alkaloids
(0,1)
|
|
04.07.04.02 |
Prophylaxis of migraine
(7,3)
|
|
04.07.04.03 |
Cluster headache
(1,0)
|
|
04.08 |
Antiepileptics
(0,0)
|
|
04.08.01 |
Control of epilepsy
(0,0)
|
|
|
Carbamazepine and Oxcarbazepine
(3,1)
|
|
|
Ethosuximide
(1,0)
|
|
|
Gabapentin and pregabalin
(2,0)
|
|
|
Lacosamide
(1,0)
|
|
|
Lamotrigine
(1,0)
|
|
|
Levetiracetam
(1,0)
|
|
|
Phenobarbital and other barbiturates
(2,0)
|
|
|
Phenytoin
(1,0)
|
|
|
Retigaine
(1,0)
|
|
|
Rufinamide
(1,0)
|
|
|
Tiagabine
(1,0)
|
|
|
Topiramate
(1,0)
|
|
|
Valproate
(1,1)
|
|
|
Vigabatrin
(1,0)
|
|
|
Zonisamide
(1,0)
|
|
|
Benzodiazepines
(2,0)
|
|
|
Other Drugs
(6,0)
|
|
04.08.02 |
Drugs used in status epilepticus
(8,1)
|
|
04.08.03 |
Febrile convulsions
(2,0)
|
|
04.09 |
Drugs used in parkinsonism and related disorders
(0,1)
|
|
04.09.01 |
Dopaminergic drugs used in Parkinsons disease
(0,0)
|
|
|
Dopamine receptor agonists
(7,0)
|
|
|
Levodopa
(3,1)
|
|
|
Monoamine-oxidase-B inhibitors
(3,0)
|
|
|
Catachol-O-methyltransferase inhibitors
(3,0)
|
|
|
Amantadine
(1,1)
|
|
04.09.02 |
Antimuscarinic drugs used in parkinsonism
(3,0)
|
|
04.09.03 |
Drugs used in essential tremor, chorea, tics, and related disorders
(6,1)
|
|
|
Torsion dystonias and other involuntary movements
(2,1)
|
|
04.09.04 |
Restless leg syndrome
(0,0)
|
|
04.10 |
Drugs used in substance dependence
(0,0)
|
|
04.10.01 |
Alcohol dependence
(3,1)
|
|
04.10.02 |
Nicotine dependence
(3,2)
|
|
04.10.03 |
Opioid dependence
(0,0)
|
|
|
Opioid substitution therapy
(3,1)
|
|
|
Adjunctive therapy and symptomatic treatment
(1,0)
|
|
|
Opioid-receptor antagonists
(1,0)
|
|
04.11 |
Drugs for dementia
(4,0)
|
|
|
|
